Hillary Clinton is finally getting a little love from Big Pharma.

The head of the Pharmaceutical Research and Manufacturers ofAmerica (PhRMA) told The Hill that his group supports the policyfloated by the leading Democratic presidential candidate, whichwould cap an individual’s monthly out-of-pocket prescription drugspending at $250.

“I would say one thing that she has proposed that we would favoris capping out-of-pocket costs,” PhRMA CEO Stephen Ubl said. “Ithink we have to acknowledge that some patients do face challengesin accessing their medicines.”

The realization of such a proposal would not directly threatendrug manufacturers, of course, since it would just require insurersto pick up a greater share of the tab of increasingly expensive medications.Insurers, of course, are not going to be enthusiastic about such apolicy.

Clinton has touted other policies that present a much greaterthreat to pharmaceutical firms, however.

She has hinted at laws to force drug manufacturers to spend agreater portion of their budgets on research and development andless on marketing, particularly direct-to-consumer advertising thatthe American Medical Association has proposed barring entirely.While Clinton stops short of proposing an all-out ban, she has saiddrug companies should not be able to write off the cost ofadvertising campaigns as a business expense for tax purposes.

Clinton has also urged for a ban on “pay for delay,” in whichpharmaceutical companies pay to postpone the introduction ofcompetition from generic versions of their drugs. She has alsocalled for Medicare to negotiate prices with drug-makers as well asto allow the re-importation of drugs from abroad.